SCHEDULE: Bering Partners Discloses 5.8% Stake in CalciMedica
Beneficial Ownership Disclosure
Bering Partners II, L.P. and its affiliates have reported a 5.8% beneficial ownership stake in CalciMedica, Inc., totaling 663,246 shares.
Summary
- Bering Partners II, L.P., Bering Partners II GP, L.L.C., Evgeny Zaytsev, and Philip Sawyer (collectively, the "Reporting Persons") have filed a Schedule 13G.
- The Reporting Persons beneficially own an aggregate of 663,246 shares of CalciMedica, Inc. Common Stock.
- This ownership represents 5.8% of CalciMedica, Inc.'s outstanding Common Stock.
- The calculation of the 5.8% stake includes 663,246 shares directly held by Bering II and 130,651 shares issuable upon the exercise of warrants held by Bering II.
- The percentage is based on 13,481,917 shares of Common Stock outstanding as of November 6, 2024, as reported in CalciMedica's Form 10-Q for the quarter ended September 30, 2024, plus the 130,651 shares from exercisable warrants.
- One warrant, originally part of a pair for 261,302 shares, expired as of December 31, 2024, reducing the exercisable shares to 130,651.
- Bering II GP, as the general partner of Bering II, may be deemed to have sole voting and dispositive power over the shares.
- Evgeny Zaytsev and Philip Sawyer, as managing members of Bering II GP, may be deemed to have shared voting and dispositive power over the shares.
Sentiment
Score: 6
Explanation: The disclosure of a significant beneficial ownership stake by an investment firm is generally a neutral to slightly positive signal, indicating investor interest and potential confidence in the company's value.
Positives
- The disclosure of a significant 5.8% stake by an institutional investor like Bering Partners II, L.P. can be interpreted as a vote of confidence in CalciMedica, Inc.'s future prospects.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: The disclosure of a new significant institutional investor may influence investor sentiment and potentially the stock price, signaling increased institutional interest in CalciMedica, Inc.
Key Dates
| Date | Description |
|---|---|
| 2024-01-23 | Date of event which requires the filing of this statement. |
| 2024-09-30 | End of the quarter for which CalciMedica, Inc.'s Form 10-Q was filed, providing the basis for outstanding shares. |
| 2024-11-06 | Date as of which 13,481,917 shares of CalciMedica's Common Stock were outstanding, as reported in the Issuer's quarterly report on Form 10-Q. |
| 2024-12-31 | Date by which one of the warrants held by Bering II GP expired, reducing the number of shares connected to exercisable warrants to 130,651. |
| 2025-10-29 | Signature date for the Schedule 13G filing by all Reporting Persons. |
Keywords
CalciMedica, Bering Partners, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Warrants, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.